Creating scalable cell therapy collection processes

As a cell and gene therapy developer, your cell collection protocol requirements and specifications will impact your apheresis center network selection strategy and your ability to efficiently scale your processes. Any time your protocols or processes differ from those in place at a center, there are likely implications for training, forms and standard operating procedures (SOPs), which can delay your first collection.

Erin Rasch, Vice President of Sales and Business Development for Be The Match BioTherapies

Maintaining business continuity during COVID-19

Just like for all businesses, March 2020 began what would become months of uncharted territory for our Be The Match BioTherapies® team. Overnight, travel to visit with cell therapy partners and potential clients was grounded. Conferences where connections are made…canceled. Even team meetings that were once in person moved online. But through these challenges, resiliency…

Depiction of international autologous cell therapy logistics.

Overcoming autologous cell therapy logistics challenges in the age of COVID-19

There is no question the COVID-19 pandemic has disrupted cell therapy logistics like never before. Supply chain challenges are no longer the exception, but the norm. So how can companies overcome autologous cell therapy logistics challenges to deliver time-sensitive source material and manufactured therapies on time? It’s not easy in our current environment, but it…

Representation of cell therapy production disruption due to COVID-19 pandemic

How COVID-19 is changing the production of cell therapies

This piece written by Joy Aho, PhD, Senior Product Manager, Be The Match BioTherapies®, was originally published on CellandGene.com in April 2020. We’re living through unprecedented times, both as individuals and as a nascent cell therapy field. The COVID-19 pandemic has had negative implications for manufacturing and shipping across nearly all industries, including very pronounced…

Representation of NMDP/Be The Match donor collection network

Managing donor collections during the COVID-19 pandemic

Even before COVID-19 reached pandemic levels, teams at the National Marrow Donor Program® (NMDP)/Be The Match® had their eye on an important part of the cell therapy supply chain—donor collections. Collections from allogeneic donors are critical to getting time-sensitive life-saving cell therapies to patients around the world. But donors often must fly to the apheresis…

Quality starting material: The driving force behind life-saving cell therapies

This piece was originally published in November 2019 on CellandGene.com We are living through one of the most exciting eras biopharmaceutical science has ever seen. Following the first U.S. and European regulatory approvals of gene therapies and CAR-T therapies in recent years, activity in this industry has skyrocketed. In the U.S., more than 800 clinical…

Efficiencies gained from the Quality System Audit Program

Three things to know about efficient qualification of collection centers

Ensuring cell collection centers and cell therapy labs are meeting FDA regulatory requirements and providing high-quality starting material for your cell or gene therapy is critical to your therapy’s success. As the industry continues to rapidly advance, it is becoming more critical to integrate process efficiencies wherever possible. There is a solution: using an established…